Abstract

This review demonstrates the role and the data supporting Reg gene peptides in forming new islet containing new populations of beta cells from one’s own progenitor cells in the pancreas. Data in man demonstrates that even those patients with 20 years of type 1 diabetes, can generate new islets with Reg gene peptides and during pregnancy when there is upregulation of REG genes. The distinctions between islets in mice and men are also described to provide an understanding of why, in man, there is a unique architecture and vascular of human islets requiring islets to function optimally within the pancreas..

Keywords: REG Gene; Reg (Protein); Reg Peptides; ISLET Neogenesis; Transplants

References

1. Barron M. “The relation of the islets of Langerhans to diabetes with special reference to cases of pancreatic lithiasis”. Surgery, Gynecology and Obstetrics 19 (1920): 437-448.
2. Banting FG and Best CH. “Pancreatic extracts”. Journal of Laboratory and Clinical Medicine 7 (1922): 464-472.
3. Banting FG., et al. “Pancreatic extracts in the treatment of diabetes mellitus. Preliminary report”. Canadian Medical Association Journal 12 (1922) 141-146.
4. De Takats G and Cuthbert FP. “Surgical attempts at increasing sugar tolerance”. Archives of Surgery (1933): 750-764.
5. DeTakats G. “Ligation of the tail of the pancreas in juvenile diabetes”. Endocrinology 14 (1930): 255-264.
6. Doniach I and Morgan AG. “Islets of Langerhans in juvenile diabetes mellitus”. Clinical Endocrinology 3 (1973): 233-248.
7. Deng S., et al. “Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects”. Diabetes3 (2004): 624-632.
8. Kilimnik G., et al. “Altered islet composition and disproportionate loss of large islets in patients with type 2 diabetes”. PLoS One11 (2011): e27445.
9. Yoon KH., et al. “Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea”. The Journal of Clinical Endocrinology and Metabolism 5 (2003): 2300-2308.
10. Togliatto G., et al. “Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes”. Diabetes 59 (2010): 1016-1025.
11. Granata R., et al. “Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta cells and human islets: involvement of 3’,5’-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling”. Endocrinology 148 (2007): 512-529.
12. Brunicardi FC., et al. “Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis”. The Journal of Clinical Endocrinology and Metabolism 81 (1996): 3566-3572.
13. Rabiee A., et al. “Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy”. Journal of Diabetes Science and Technology 5 (2011): 1521-1528.
14. Levetan C., et al. “Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps”. Diabetes Care 26 (2003): 1-8.
15. Bergenstal RM., et al. “Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes”. The New England Journal of Medicine 363 (2010): 311-320.
16. Bergenstal RM., et al. “Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase”. Diabetes Care 34 (2011): 2403-2405.
17. Christiansen JS. “What is normal glucose? – Continuous glucose monitoring data from healthy subjects”. EASD, Copenhagen, The 42^nd Annual Meeting of the EASD, Copenhagen, Denmark (2006).
18. DCCT Research Group. “The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial”. Diabetes 45 (1996): 1289-1298.
19. Stratton IM., et al. “Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study”. BMJ: British Medical Journal on JSTOR 321 (2000): 405-412.
20. Khaw KT., et al. “Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)”. BMJ: British Medical Journal on JSTOR 322 (2001): 15-18.
21. Russell SJ., et al. “Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes”. The New England Journal of Medicine 371 (2014): 313-325.
22. Cabrera O., et al. “The unique cytoarchitecture of human pancreatic islets has implications for islet cell function”. Proceedings of the National Academy of Sciences of the United States of America 103 (2006): 2334-2339.
23. Brissova M., et al. “Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy”. Journal of Histochemistry and Cytochemistry 53 (2005): 1087-1097.
24. Kim A., et al. “Islet architecture: A comparative study”. Islets 1 (2009): 129-136.
25. Rodriguez-Diaz R., et al. “Innervation patterns of autonomic axons in the human endocrine pancreas”. Cell Metabolism 14 (2011): 45-54.
26. Bosco D., et al. “Unique arrangement of alpha- and beta-cells in human islets of Langerhans”. Diabetes 59 (2010): 1202-1210.
27. Orci L and Unger RH. “Functional subdivision of islets of Langerhans and possible role of D cells 1976”. Lancet 2 (1975): 1243-1244.
28. Orci L. “The microanatomy of the islets of Langerhans”. Metabolism11-1 (1976):1303-1313.
29. Bonner-Weir S and O’Brien TD. “Islets in type 2 diabetes: in honor of Dr. Robert C. Turner”. Diabetes 57 (2008): 2899-2904.
30. Unger RH and Cherrington AD. “Glucagonocentric restructuring of diabetes: pathophysiologic and therapeutic makeover”. Journal of Clinical Investigation 122 (2012): 4-12.
31. Levetan C., et al. “Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps”. Diabetes Care 26 (2003): 1-8.
32. Bonner-Weir., et al. “The pancreatic ductal epithelium serves as a potential pool of progenitor cells”. Pediatr Diabetes2 (2004): 16-22.
33. Inada A., et al. “Carbonic anhydrase II-positive 36. pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth”. Proceedings of the National Academy of Sciences of the United States of America 50 (2008): 19915-19919.
34. Lechner A and Habener JF. “Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus”. The American Journal of Physiology: Endocrinology and Metabolism 284 (2003): 259-266.
35. Davani B., et al. “Human islet-derived precursor cells can cycle between epithelial clusters and mesenchymal phenotypes”. Journal of Cellular and Molecular Medicine .8b (2009): 2570-2581.
36. Watanabe T., et al. “Pancreatic beta cell replication and amelioration of surgical diabetes by Reg protein”. Proceedings of the National Academy of Sciences of the United States of America 91 (1994): 3589-3592.
37. Xia F., et al. “Reg3g overexpression promotes β cell regeneration and induces immune tolerance in nonobese-diabetic mouse model”. Journal of Leukocyte Biology 6 (2016): 1131-1140.
38. Okamoto H. “The Reg gene family and Reg proteins, with special attention to the regeneration of pancreatic beta-cells”. Japanese Society of Hepato-Biliary-Pancreatic Surgery 6 (1999): 254-262.
39. Unno M., et al. “Islet beta-cell regeneration and reg genes”. Advances in Experimental Medicine and Biology 321 (1992): 61-66.
40. Akiyama T., et al. “Activation of Reg gene, a gene for 43. insulin-producing beta -cell regeneration: poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation”. Proceedings of the National Academy of Sciences of the United States of America 1 (2001): 48-53.
41. Saitoh S., et al. “Distinct Cell Clusters Touching Islet Cells Induce Islet Cell Replication in Association with Over-Expression of Regenerating Gene (REG) Protein in Fulminant Type 1 Diabetes”. PLoS One4 (2014): e95110.
42. Newgard CPA., et al. “The Reg gene is preferentially expressed in the exocrine pancreas during islet regeneration”. Diabetes1 (1989): 49A.
43. Terazono K., et al. “A novel gene acti46. vated in regenerating islets”. Journal of Biological Chemistry 263 (1988): 2111-2114.
44. Terazono K., et al. “Expression of reg protein in rat regenerating islets and its co- localization with insulin in the beta-cell secretory granules”. Diabetologia 33 (1990): 250-252.
45. Miyaura C., et al. “Expression of reg/PSP, a pancreatic exocrine gene: relationship to changes in islet beta-cell mass”. Molecular Endocrinology 5 (1991): 226-234.
46. Gross DJ., et al. “Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced, immunoregulation combined with Reg protein treatment”. Endocrinology 139 (1998): 2369-2374.
47. Ota H., et al. “Pancreatic β cell proliferation by intermittent hypoxia via up-regulation of Reg family genes and HGF gene”. Life Sciences 18-19 (2013): 664-672.
48. Wang Y., et al. “Coordinated age-dependent and pancreatic-specific expression of mouse Reg2, Reg3α, and Reg3β genes”. Growth Factors2-3 (2011): 72-81.
49. Liu JL., et al. “Possible roles of reg family proteins in pancreatic islet cell growth”. Endocrine, Metabolic and Immune Disorders - Drug Targets 1 (2008): 1-10.
50. Chen T., et al. “Role of INGAP-pp in the differentiation of hUCMSCs into insulin producing cells”. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi2 (2013): 141-145.
51. Calderari S., et al. “Regenerating 1 and 3b gene expression in the pancreas of type 2 diabetic Goto-Kakizaki (GK) rats”. PLoS One2 (2014): e90045.
52. Lu Y., et al. “Activation of the Reg family genes by pancreatic-specific IGF-I gene deficiency and after streptozotocin-induced diabetes in mouse pancreas”. The American Journal of Physiology: Endocrinology and Metabolism 1 (2006): E50-58.
53. Huszarik K., et al. “Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice”. Journal of Immunology 9 (2010): 5120-5129.
54. Zenilman ME., et al. “Pancreatic regeneration (reg) gene expression in a rat model of islet hyperplasia”. Surgery5 (1996): 576-584.
55. Dusetti NJ., et al. “Induction 59. of lithostathine/reg mRNA expression by serum from rats with acute pancreatitis and cytokines in pancreatic acinar AR-42J cells”. Biochimica et Biophysica Acta 330 (1996): 129-132.
56. Kobayashi S., et al. “Identification of a receptor for REG (Regenerating gene) protein, a pancreatic beta-cell regeneration factor”. Journal of Biological Chemistry 275 (2000): 10723-10726.
57. Zenilman ME., et al. “Effect of reg protein on rat pancreatic ductal cells”. Pancreas 17 (1998): 256-261.
58. Graf R., et al. “Exocrine meets endocrine: pancreatic stone protein and regenerating protein-two sides of the same coin”. Journal of Surgical Research 133 (2006): 113-120.
59. Orelle B., et al. “Human pancreatitis-associated protein: messenger RNA cloning and expression in pancreatic diseases”. Journal of Clinical Investigation 90 (1992): 2284-2291.
60. Vasseur S., et al. “p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I”. Journal of Biological Chemistry 8 (2004): 7199-7207.
61. Zenilman ME., et al. “Pancreatic thread protein is mitogenic to pancreatic-derived cells in culture”. Gastroenterology 110 (1996): 1208-1214.
62. Iovanna J., et al. “Messenger RNA sequence and expression of rat pancreatitis-associated protein, a lectin-related protein overexpressed during acute experimental pancreatitis”. Journal of Biological Chemistry 36 (1991): 24664-24669.
63. Mouse Genomics Informatics. “Mus musculus 11 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:5033401N17 product: regenerating islet-derived 1, full insert sequence.
64. Unno M., et al. “Production and characterization of REG knockout mice: reduced proliferation of pancreatic beta-cells in REG knockout mice”. Diabetes 51 (2002): S478-483.
65. Assouline-Thomas B., et al. “Islet Neogenesis Associated Protein (INGAP) induces the differentiation of an adult human pancreatic ductal cell line into insulin-expressing cells through stepwise activation of key transcription factors for embryonic beta cell development”. Differentiation4-5 (2015): 77-90.
66. Levetan C. “Distinctions between islet neogenesis and β-cell replication: implications for reversal of Type 1 and 2 diabetes”. Journal of Diabetes 2 (2010): 76-84.
67. Levetan CS., et al. “Discovery of a human peptide sequence signaling islet neogenesis”. Endocrine Practice 9 (2008): 1075-1083.
68. Kapur R., et al. “Short-term effects of INGAP and Reg family peptides on the appearance of small β-cells clusters in non-diabetic mice”. Islets1 (2012): 40-48.
69. Rosenberg L and Vinik AI. “Induction of endocrine cell differentiation: a new approach to management of diabetes”. Journal of Laboratory and Clinical Medicine 114 (1989): 75.
70. Lipsett M., et al. “The role of isletneogenesis-associated protein (INGAP) in islet neogenesis”. Cell Biochemistry and Biophysics 2-3 (2007): 127-137.
71. Barbosa H., et al. “Islet Neogenesis Associated Protein (INGAP) modulates gene expression in cultured neonatal rat islets”. Regulatory Peptides Journal 1-3 (2006): 78-84.
72. Lipsett M., et al. “INGAP: A critical mediator of islet neogenesis?” Diabetes1 (2003): A360.
73. Rosenberg L., et al. “A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice”. Annals of Surgery 5 (2004): 875-884.
74. Pittenger GL., et al. “Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs”. Pancreas1 (2007): 103-111.
75. Rosenberg L., et al. “A pentadecapeptide fragment 91. of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice”. Annals of Surgery 240 (2004): 875-884.
76. Ilic S., et al. “Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant Type I diabetic women?” Diabetologia10 (2000): 1329-1330.
77. Ratner RE., et al. “Double-Blind, Placebo Controlled Trial of Islet Neogenesis Gene Associated Protein (INGAP) in Type 1 Diabetes (T1D) Subjects (2005).
78. Ratner RE., et al. “Double-Blind, Placebo Controlled Trial of Islet Neogenesis Gene Associated Protein (INGAP) Therapy in Type 2 Diabetes (T2DM) Subjects (2005).
79. Dungan KM., et al. “Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)”. Diabetes/Metabolism Research and Reviews 6 (2009): 558-565.
80. Watkins E., et al. “Effect of Human Proislet Peptide 2B on ß-Cell Function in Subjects with Metformin-Treated Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study”.
81. Guo., et al. “Pancreatic Regeneration after Partial Pancreatectomy in Mice Mirrors that in Rats with both Enhanced Replication and Neogenesis.”.Diabetes 59.1 (2010): 2589-OP.
82. Levetan C. “Distinctions between islet neogenesis and β-cell replication: implications for reversal of Type 1 and 2 diabetes”. Journal of Diabetes 2 (2010): 76-84.
83. Levetan C., et al. “Proposal for generating new beta cells in a muted immune environment for type 1 diabetes”. Diabetes/Metabolism Research and Reviews 8 (2013): 604-606.